OPTN (Option Therapeutics) Net Margin %: 0.00% (As of Dec. 2025)


What is Option Therapeutics Net Margin %?

Option Therapeutics OPTN Net Margin % is 0.00% as of Dec. 2025.

Net margin is calculated as Net Income divided by its Revenue. Option Therapeutics's Net Income for the three months ended in Dec. 2025 was $-0.19 Mil. Option Therapeutics's Revenue for the three months ended in Dec. 2025 was $0.00 Mil. Therefore, Option Therapeutics's net margin for the quarter that ended in Dec. 2025 was 0.00%.

The historical rank and industry rank for Option Therapeutics's Net Margin % or its related term are showing as below:


OPTN's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -89.56
* Ranked among companies with meaningful Net Margin % only.

Option Therapeutics  (AMEX:OPTN) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Option Therapeutics Net Margin % Related Terms

Option Therapeutics Net Margin % Historical Data

* Premium members only.

The historical data trend for Option Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Option Therapeutics Net Margin % Chart

Option Therapeutics Annual Data
Trend Jun24 Jun25
Net Margin %
0.00 0.00

Option Therapeutics Quarterly Data
Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
Net Margin % Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

OPTN vs : Net Margin % Comparison

For the Biotechnology subindustry, Option Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Option Therapeutics Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Option Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Option Therapeutics's Net Margin % falls into.


Option Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Option Therapeutics's Net Margin for the fiscal year that ended in Jun. 2025 is calculated as

Net Margin=Net Income (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-1.224/0
= %

Option Therapeutics's Net Margin for the quarter that ended in Dec. 2025 is calculated as

Net Margin=Net Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-0.189/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Option Therapeutics (OPTN) has a Net Margin % of 0.00% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Option Therapeutics and its competitors.
Is Option Therapeutics' Net Margin % too high?
Option Therapeutics' current Net Margin % is 0.00%.
How does Option Therapeutics' Net Margin % compare to ?
Option Therapeutics' Net Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Option Therapeutics and its competitors. Option Therapeutics's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Option Therapeutics stock overvalued right now?
Option Therapeutics (OPTN) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Option Therapeutics (OPTN), the current Net Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Option Therapeutics Business Description

Comparable Companies
Address 680 West Nye Lane, Suite 201, Carson, NV, USA, 89703
Option Therapeutics Inc is a clinical-stage company developing inventive drug therapies to treat debilitating and life-threatening liver disease through its investigational drug candidate BIV201 (continuous infusion terlipressin). BIV201 is administered as a patent-pending liquid formulation of terlipressin with patents issued, to date, in the U.S., China, Japan, Chile, and India.